ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

narazaciclib

Also written as “HX301+/Temozolomide”, “HX301” and “Narazaciclib”.

Its studies are mostly in Glioma · Endometrial Neoplasms, led by 2 companies.

Drug pageON123300: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Nov 21, 20244 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Hanx Biopharmaceuticals21 open or runningphase 2since Nov 21, 2024Jan 29, 2023Dec 31, 2026phase 2 · NCT06703255
Traws Pharmaits history only22 open or runningphase 2since Jan 19, 2023Jan 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hangzhou Hanx Biopharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2022Named narazaciclibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, HX301, ON123300
  2. Jan 29, 2023First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05731934 · 20 enrolled · China
  3. Nov 21, 2024Phase 2 study in GliomaNCT06703255 · 72 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in GliomaNCT06703255

TargetBeta

“An orally bioavailable inhibitor of NUAK family SNF1-like kinase 1 (AMPK-related protein kinase 5; ARK5), and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), ”NCIt, by rule

Studies

All 2 Hangzhou Hanx Biopharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06703255Glioma · China2RecruitingDec 31, 202672
NCT05731934Advanced Solid Tumors · China1CompletedJan 12, 202420

How it is read

Names in the registry

  • “HX301+/Temozolomide”, 1 entry
  • “HX301”, 1 entry
  • “Narazaciclib”, 1 entry
  • “ON123300”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.